Opportunities and challenges for antisense oligonucleotide therapies

Antisense oligonucleotide (AON) therapies involve short strands of modified nucleotides that target RNA in a sequence‐specific manner, inducing targeted protein knockdown or restoration. Currently, 10 AON therapies have been approved in the United States and Europe. Nucleotides are chemically modifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuijper, Elsa C., Bergsma, Atze J., Pijnappel, W.W.M. Pim, Aartsma‐Rus, Annemieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Ssiem Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891411/
https://www.ncbi.nlm.nih.gov/pubmed/32391605
http://dx.doi.org/10.1002/jimd.12251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891411/
https://www.ncbi.nlm.nih.gov/pubmed/32391605
http://dx.doi.org/10.1002/jimd.12251

Ejemplares similares